"Adchibadem Citi Clinic MBAL Tokuda" EAD, Sofia
Welcome,         Profile    Billing    Logout  
 0 Trials 
1 Trials


Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Georgieva, Svetlana
MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Calendar Jan 2023 - Jan 2023: From MIRASOL trial for high-grade epithelial ovarian cancer
Calendar Jul 2022 - Sep 2022: Approval for high-grade epithelial ovarian cancer (based on MIRASOL trial)
Checkmark Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
Checkmark [VIRTUAL] MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with hi.…
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
ImmunoGen, Inc., Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

Download Options